Tirzepatide Monthly Cost
The monthly cost of tirzepatide (Mounjaro®/Zepbound®) is approximately $1,017-$1,283 based on the most recent national pricing data, though individual out-of-pocket costs vary significantly depending on insurance coverage and available manufacturer discounts.
Current Pricing Data
Based on the 2025 American Diabetes Association Standards of Care 1, the most recent national pricing for tirzepatide shows:
- Average Wholesale Price (AWP): $1,272-$1,283 per month for maintenance doses (5,10, or 15 mg weekly)
- National Average Drug Acquisition Cost (NADAC): $1,017-$1,030 per month 1, 2
The 2025 AACE Consensus Statement 3 confirms similar pricing, with tirzepatide formulated as once-weekly subcutaneous injections titrated from 2.5 mg to a maximum of 15 mg weekly.
Important Cost Considerations
Insurance Coverage Context
These national average prices represent list prices before insurance or manufacturer assistance programs. The evidence explicitly notes that "costs listed may not be representative of an individual's cost and do not account for medication coverage or available discounts" 1.
Comparative Pricing
For context, tirzepatide's monthly cost is:
- Similar to semaglutide: $1,296 (NADAC) for Wegovy®/Ozempic® 1
- Lower than liraglutide: $1,296 (NADAC) for Saxenda® 1
- Substantially higher than older agents: Metformin costs $1-3/month (NADAC) 2
Real-World Cost Offsets
Recent real-world data 4 suggests that for persistent users over 12-18 months, healthcare cost offsets may partially compensate for medication costs, with monthly savings of $319 (ranging $94-$544) in non-medication healthcare costs in older adults with obesity. However, this does not eliminate the substantial upfront medication expense.
Clinical Value Perspective
Tirzepatide demonstrates superior efficacy compared to alternatives, achieving 22.5% weight loss at the 15 mg dose in the SURMOUNT-1 trial, with nearly 40% of participants losing ≥25% body weight 3. In type 2 diabetes, it produces HbA1c reductions of 1.9-2.2% with >87% reaching target HbA1c <7% 3.
Cost-Effectiveness Analysis
A 2022 cost-effectiveness study 5 found tirzepatide versus background therapy had an incremental cost-effectiveness ratio of $59,000 per quality-adjusted life year (QALY), which falls within commonly accepted willingness-to-pay thresholds of $50,000-$150,000 per QALY 6.
Practical Guidance
Patients should:
- Check insurance formulary coverage before initiating therapy
- Explore manufacturer savings programs (often available for commercially insured patients)
- Discuss Medicare Part D coverage if eligible (coverage varies by plan)
- Consider the 2.5 mg starting dose costs similarly to maintenance doses, as pricing is per injection rather than per milligram
The substantial monthly cost remains a major barrier to access, despite strong clinical efficacy data across multiple outcomes including glycemic control, weight loss, cardiovascular risk reduction, and improvement in conditions like obstructive sleep apnea 3.